OncoDxRx invents predictive drug response technology for cancer patients with limited therapy options
The PGA platform has shown its real value in clinical decision-making, proving to be an essential tool that should equip all modern diagnostic labs.
- (1888PressRelease) July 20, 2024 - Researchers at OncoDxRx have developed a drug response predictive technology that is effective at predicting which drugs are likely to benefit a patient who is unresponsive to precision therapy.
In findings published in Onco (https://www.mdpi.com/2673-7523/4/3/12), therapy plan guided by the PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) technology outperformed current standard-of-care treatment strategy.
Cancer is the main cause of death. However, while early diagnosis is critical for more effective intervention and better outcomes, the effective tools available, are often still insensitive, costly, invasive, and are not accessible for all patients.
In the one-of-its-kind platform, the OncoDxRx team established patient-derived gene expression signature using cell-free mRNA profiling. The data are collected noninvasively, and are low-cost, real-life and real-time. The team then mapped out the most effective cancer drugs using the signature data through a proprietary data transformation and translation process.
"To make sure PGA has the potential to be adopted in a healthcare setting, we trained and tested it on routinely-collected data not just from database cohorts, but from patients in actual practice clinics. This shows PGA will be generalizable to a real-world setting," OncoDxRx said.
The results showed that PGA-supported treatment strategy was more effective than the standard clinical practice in improving patient outcomes. This has the potential to significantly benefit patient well-being, showing which drugs are most likely to work, while removing the anxiety for those patients with limited treatment options.
At a time of intense pressure on healthcare resources, this will also help remove the need for unnecessary invasive and costly diagnostic tests.
In recent work, the OncoDxRx team has applied the technology to cover three types of cancers, lung, breast and pancreatic.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam